Ovation Science Sees Expanded Opportunities for Its Topical Products Following U.S. Cannabis Rescheduling

Executive Summary

• The U.S. Executive Order rescheduling cannabis is expected to reduce regulatory barriers and create opportunities for Ovation Science’s THC‑free transdermal CBD topicals, including potential Medicare reimbursement.
• Ovation highlights its proprietary Invisicare® delivery technology, which it says achieves 82% CBD bioavailability versus 2–3% for competing topicals, positioning the company for expanded licensing and sales in the U.S. market.
• Management views the regulatory change as a positive catalyst for future revenue growth through increased licensing opportunities, research collaborations, and broader consumer adoption.

Key Details

• The Executive Order reclassifies cannabis at the federal level, potentially allowing CBD‑based products to be considered for Medicare coverage.
• Ovation estimates that ~68 million Americans are enrolled in Medicare, with roughly 35% experiencing inflammation‑related conditions (e.g., arthritis).
• Company’s Invisicare® technology delivers CBD through the skin with reported bioavailability of 82%, compared to 2–3% for competing topicals and ≈6% for oral CBD products.
• Ovation currently licenses its topical formulations in four U.S. states and sells under its own brands (ARLO CBD Beauty, InVibe® MD).
• President Terry Howlett stated the rescheduling “creates expanded opportunities…for licensing our topical products to companies seeking to expand into the U.S. market.”
• The company plans to pursue growth in the United States as well as internationally (Canada, Europe, Australia).

Notable Quotes

“We are very encouraged by this transformative announcement from the White House and see it as a significant opportunity to license our topical products to companies seeking to expand into the U.S. market,” – Terry Howlett, President, Ovation Science.